8-K: Vireo Growth Expands Colorado Footprint with PharmaCann Asset Buy

Vireo Growth Inc. announced an Asset Purchase Agreement to acquire certain retail assets and properties from PharmaCann Inc. in Colorado for $49 million in subordinate voting shares.

Summary

• Vireo Health, Inc., a wholly-owned subsidiary of Vireo Growth Inc., entered into an Asset Purchase Agreement (APA) with PharmaCann Inc. and its subsidiaries on December 16, 2025.
• The Buyer will purchase assets related to certain cannabis dispensaries operated by Seller Parties in the State of Colorado (the "Dispensaries").
• Consideration for the Purchased Assets is $49,000,000.00, payable in subordinate voting shares of Vireo Growth Inc. to Argent Institutional Trust Company, plus the assumption of certain liabilities.
• The share consideration is subject to positive and negative adjustments based on inventory levels, trade payables of the acquired dispensaries, and the occurrence of certain other events by the closing date.
• An affiliate of Vireo has entered into a Management Services Agreement, dated December 16, 2025, to provide management services to the Dispensaries until the closing date.
• The transaction is expected to close during the first half of calendar year 2026, subject to satisfaction of closing conditions and state and local regulatory approvals.
• This acquisition will expand Vireo's position in Colorado's adult-use retail market to 41 total active dispensaries.

Sentiment

Score: 7

Explanation: The announcement of an acquisition that expands market presence and aligns with stated strategy is generally positive, though subject to closing conditions and integration risks. The consideration is in shares, which avoids immediate cash outflow but could dilute existing shareholders.

Positives

• Expands Vireo's operating footprint in Colorado with the addition of 17 dispensaries.
• Increases Vireo's leadership position in the Colorado retail market to 41 total dispensaries.
• Reflects a continuation of Vireo's strategy to grow its business through accretive mergers and acquisitions (M&A).
• Complements other recently acquired assets in Colorado, enhancing market synergy.

Risks

• Potential adverse impact of the transactions on Vireo's business, financial condition, and results of operations.
• Uncertainty regarding Vireo's ability to successfully consummate the transactions contemplated by the APA.
• Challenges in maintaining relationships with suppliers, customers, employees, and other third parties as a result of the transactions.
• Potential effects of the transactions on the Company and the interests of various constituents.
• Risks and uncertainties associated with the transactions, some of which are beyond Vireo's control.
• The nature, cost, impact, and outcome of pending and future litigation, other legal or regulatory proceedings, or governmental investigations and actions.
• Risks related to the timing and content of adult-use legislation in markets where the Company currently operates.
• Current and future market conditions, including the market price of the subordinate voting shares of the Company.
• Risks related to epidemics and pandemics.
• Impact of federal, state, local, and foreign government laws, rules, and regulations, including those relating to cannabis operations in the United States and any changes to such laws or regulations.
• Operational, regulatory, and other risks; challenges in execution of business strategy and management of growth.
• Difficulties inherent in forecasting future events; potential conflicts of interest.
• Risks inherent in an agricultural business and a manufacturing business.
• Liquidity concerns and the ability of the Company to raise additional financing to continue as a going concern.
• The Company's ability to meet the demand for flower in its various markets.
• Ability to dispose of assets held for sale at an acceptable price or at all.
• The transactions remain subject to material conditions, including satisfaction of all conditions to the APA, with no assurance of completion.

Future Outlook

The company expects the transaction to close in the first half of 2026, subject to regulatory approvals and satisfaction of closing conditions. This acquisition is part of a strategy to continue growing the business through accretive M&A and will complement other recently acquired assets in Colorado.

Management Comments

• "We are pleased to announce this transaction which reflects the continuation of our strategy to continue growing our business through accretive M&A. This transaction will complement our other recently acquired assets in Colorado." John Mazarakis, Chief Executive Officer.

Industry Context

The acquisition significantly expands Vireo's presence in the Colorado adult-use retail cannabis market, increasing its dispensary count to 41. This move indicates a consolidation trend and strategic expansion within the competitive U.S. cannabis industry, particularly in established markets like Colorado, aiming to strengthen market leadership.

Legal Proceedings

• The filing mentions risks related to "the nature, cost, impact and outcome of pending and future litigation, other legal or regulatory proceedings, or governmental investigations and actions" as a general forward-looking risk, but no specific current legal proceedings are disclosed in relation to this transaction.

Stakeholder Impact

• Shareholders: Potential dilution due to the issuance of subordinate voting shares as consideration; potential for increased value through expanded market presence and accretive M&A.
• Employees: Potential impacts on employees of both Vireo and PharmaCann's acquired dispensaries due to integration processes.
• Customers: Expanded retail footprint in Colorado could offer more access or choice for adult-use cannabis consumers.
• Suppliers and Third Parties: Risks mentioned regarding maintaining relationships with these parties post-transaction.

Next Steps

• Obtaining all required regulatory approvals (state and local) for the transaction.
• Satisfaction of all closing conditions set forth in the Asset Purchase Agreement (APA).
• Closing of the transaction, which is expected in the first half of 2026.
• Filing of the full APA as an exhibit to the Company's Annual Report on Form 10-K for the year ending December 31, 2025.

Key Dates

Recommendation

The acquisition is a strategic move that significantly expands Vireo's market presence in Colorado, aligning with its stated M&A strategy. While the consideration is in shares, which could lead to dilution, the addition of 17 dispensaries to a total of 41 is a substantial growth step. However, the transaction is subject to regulatory approvals and closing conditions, and the cannabis industry carries inherent regulatory and market risks. A "hold" recommendation reflects the positive strategic direction balanced with the execution risks and the broader industry uncertainties. Investors should monitor the successful closing and integration of the assets.

Keywords

Cannabis, Dispensaries, Acquisition, Colorado, Retail, M&A, Vireo Growth, PharmaCann, Asset Purchase, Marijuana, Adult-use